Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (887)	1/8/2004 3:18:26 PM
From: tuck	Read Replies (1) \| Respond to of 1005

>>MADISON, Wis. and TOKYO, Jan. 8 /PRNewswire-FirstCall/ -- Third Wave Technologies Inc. (Nasdaq: TWTI - News) today announced that it has extended its multi-year, multi-million dollar partnership with BML Inc. of Tokyo, the second largest clinical reference laboratory in Japan, for a minimum of one year. The companies will continue their collaboration to commercialize molecular diagnostic tests for infectious disease, genetic testing and pharmacogenomics. Third Wave and BML in December 2000 entered into a development and commercialization agreement that has successfully expanded BML's molecular diagnostic testing capabilities through its use of Third Wave's proprietary Invader® technology. The Invader® platform is a unique genetic analysis technology based on the natural, inherently accurate process of DNA repair. It provides superior accuracy, throughput, and ease of use, as compared to other analysis tools. "BML is very pleased to continue our very successful collaboration with Third Wave," said Motoyoshi Arai, president of BML. "Third Wave's Invader® technology is enabling us to develop superior products for molecular diagnostic testing and to offer high-value molecular diagnostic services to Japanese doctors and patients. We predict that molecular diagnostic testing will become the largest growing segment of the Japanese diagnostic market and Third Wave's Invader® technology is playing a major role in that expansion." "BML's expertise and large customer base in Japan is accelerating the adoption of Third Wave's Invader® technology for molecular diagnostic testing in this important market," said John Puisis, president and chief operating officer of Third Wave. "The extension of the companies' commercialization partnership is another strong validation of Third Wave's Invader® technology. It highlights our continuing success in driving customer adoption not only in the United States, but in the rapidly growing Japanese market as well. BML is a world-class partner and we look forward to stepping up our joint efforts with them." About BML BML, founded 48 years ago and listed on the Tokyo Stock Exchange, provides a wide-range of laboratory testing from biochemical and hematological tests to specialty tests such as RIA, cellular immunological and DNA genetic analyses, to serve all clinical and medical needs enhanced by added operations of CRC. BML operates efficiently and economically utilizing in-house developed automation systems named "Frontier" and "Symphony," to serve more than 100,000 patients a day. In addition, BML has developed a proprietary "Electronic Patients Charts" network system to support total medical care, which is all-inclusive medical information system for the next generation. For more information about BML and its services, please visit the BML's website at www.bml.co.jp. << snip Cheers, Tuck